## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 7.3% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($138.91)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Illumina’s Crossroads: Genomics Pioneer Tests Investor Patience As Wall Street Reassesses The Story**
- Source: AD HOC NEWS | 20260104T185402 | Neutral | Relevance: 100%
- Illumina's stock has seen a slight dip amidst market caution, as the company works to resolve regulatory issues and refocus on its core sequencing growth. Investors are weighing whether the genomics pioneer is a turnaround success in the making or a cautionary tale, with sentiments shifting from earlier optimism. The market awaits clear signals regarding the divestiture of Grail, disciplined capital allocation, and re-accelerating sequencing demand to determine its future trajectory.

**2. Illumina (NASDAQ:ILMN) Lowered to "Hold" Rating by Wall Street Zen**
- Source: MarketBeat | 20260104T010956 | Somewhat-Bearish | Relevance: 100%
- Wall Street Zen downgraded Illumina (NASDAQ:ILMN) from a "buy" to a "hold" rating, contributing to a consensus "Hold" rating among analysts with an average price target of $118.31. Despite the downgrade, Illumina surpassed Q3 earnings estimates with EPS of $1.34 against expectations of $1.16 and revenue of $1.08 billion, also providing a strong FY2025 guidance. The company, trading within a 52-week range of $68.70–$153.06, holds a market capitalization of $20.53 billion, with institutional investors owning approximately 89.4% of the stock.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Guggenheim | $144 | $114 | +26% |
| 2025-12-22 | Canaccord Genui | $130 | $112 | +16% |
| 2025-12-15 | Barclays | $110 | $100 | +10% |
| 2025-12-15 | JP Morgan | $130 | $105 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Guggenheim | main | Buy |
| 2025-12-22 | Canaccord Genui | main | Hold |
| 2025-12-15 | Barclays | main | Underweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.06M) |
| Sells | 10 ($80.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Heavy insider selling: $80M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Momentum building: MRS_10 improving +8.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 29.2x stretched relative to 7% growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($80.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.6B |
| Beta | 1.41 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 7.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 29.2 |
| Current P/E | 31.2 |
| YoY Growth | 7.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.2% to 7.3% (+8.5% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (7.3% > 6.0%), caution on chasing. MRS_5 at 6.3% confirms short-term momentum alignment. Outperforming sector by 5.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 73, risk of mean reversion. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 7.32% (CS: 91) | Strong |
| RSI_14 | 72.8 | Overbought |
| MACD Histogram | 0.35 | Bullish |
| vs SMA20 | 1.093x | Above |
| vs SMA50 | 1.171x | Above |
| vs SMA200 | 1.478x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $147.11
- **Stop Loss:** $138.91 (5.6% risk)
- **Target:** $155.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 160
- **Position Value:** $23,537.60
- **Portfolio %:** 23.54%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*